Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses

Sponsor
Alcon Research (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05886894
Collaborator
(none)
340
6

Study Details

Study Description

Brief Summary

The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term performance and safety of Air Optix plus HydraGlyde Multifocal soft contact lenses in a real-world setting when worn as daily wear or extended (overnight) wear.

Condition or Disease Intervention/Treatment Phase
  • Device: Lotrafilcon B multifocal soft contact lenses
  • Device: Comfilcon A multifocal soft contact lenses

Detailed Description

This is a non-interventional/observational study designed as a retrospective chart review. Study sites will identify charts within their existing databases in a fair and consistent manner, e.g., reviewing all eligible charts in reverse chronological order by year of baseline visit. The baseline visit will be defined as the first office visit where an eye care practitioner provided an in-person office biomicroscopy exam to the patient, before or during which a contact lens prescription for the study or comparator contact lenses was released. Subjects/charts meeting the eligibility criteria will be enrolled in the study.

Study Design

Study Type:
Observational
Anticipated Enrollment :
340 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Air Optix Plus HydraGlyde Multifocal Daily/Extended Wear Contact Lenses
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Air Optix plus HydraGlyde Multifocal Daily Wear

Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes and removed daily for cleaning and disinfection

Device: Lotrafilcon B multifocal soft contact lenses
Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
Other Names:
  • Air Optix plus HydraGlyde Multifocal Daily Wear
  • Air Optix plus HydraGlyde Multifocal Extended Wear
  • Air Optix plus HydraGlyde Multifocal Extended Wear

    Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes worn on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).

    Device: Lotrafilcon B multifocal soft contact lenses
    Commercially available soft (hydrophilic) contact lenses indicated for the correction of presbyopia, with or without myopia or hyperopia
    Other Names:
  • Air Optix plus HydraGlyde Multifocal Daily Wear
  • Air Optix plus HydraGlyde Multifocal Extended Wear
  • Biofinity Multifocal Daily Wear

    Comfilcon A multifocal soft contact lenses worn in both eyes and removed daily for cleaning and disinfection

    Device: Comfilcon A multifocal soft contact lenses
    Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
    Other Names:
  • Biofinity Multifocal Daily Wear
  • Biofinity Multifocal Extended Wear
  • Biofinity Multifocal Extended Wear

    Comfilcon A multifocal soft contact lenses worn in both eyes worn on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).

    Device: Comfilcon A multifocal soft contact lenses
    Commercially available soft (hydrophilic) contact lenses indicated for the correction of refractive ametropia (myopia and hyperopia) and emmetropia with presbyopia
    Other Names:
  • Biofinity Multifocal Daily Wear
  • Biofinity Multifocal Extended Wear
  • Outcome Measures

    Primary Outcome Measures

    1. Distance visual acuity at 1 year - Daily Wear [Year 1]

      The subject's chart will be reviewed for distance visual acuity at Year 1, defined as the visit which occurred 1 year (-2/+4 months) since baseline, during which period the subject was wearing the protocol required contact lenses and a contact lens examination was performed. This outcome measure is prespecified for the daily wear arms (Air Optix plus HydraGlyde Multifocal Daily Wear and Biofinity Multifocal Daily Wear).

    2. Near visual acuity at 1 year - Daily Wear [Year 1]

      The subject's chart will be reviewed for near visual acuity at Year 1, defined as the visit which occurred 1 year (-2/+4 months) since baseline, during which period the subject was wearing the protocol required contact lenses and a contact lens examination was performed. This outcome measure is prespecified for the daily wear arms (Air Optix plus HydraGlyde Multifocal Daily Wear and Biofinity Multifocal Daily Wear).

    3. Distance visual acuity at 3 years - Extended Wear [Year 3]

      The subject's chart will be reviewed for distance visual acuity at Year 3, defined as the visit which occurred 3 years (-2/+8 months) since baseline, during which period the subject was wearing the protocol required contact lenses and a contact lens examination was performed. This outcome measure is prespecified for the extended wear arms (Air Optix plus HydraGlyde Multifocal Extended Wear and Biofinity Multifocal Extended Wear).

    4. Near visual acuity at 3 years - Extended Wear [Year 3]

      The subject's chart will be reviewed for near visual acuity at Year 3, defined as the visit which occurred 3 years (-2/+8 months) since baseline, during which period the subject was wearing the protocol required contact lenses and a contact lens examination was performed. This outcome measure is prespecified for the extended wear arms (Air Optix plus HydraGlyde Multifocal Extended Wear and Biofinity Multifocal Extended Wear).

    5. Incidence of corneal infiltrative events - Daily Wear [Up to Year 1]

      The subject's chart will be reviewed for incidences of corneal infiltrative events occurring after the baseline exam. This outcome measure is prespecified for the daily wear arms (Air Optix plus HydraGlyde Multifocal Daily Wear and Biofinity Multifocal Daily Wear).

    6. Incidence of corneal infiltrative events - Extended Wear [Up to Year 3]

      The subject's chart will be reviewed for incidences of corneal infiltrative events occurring after the baseline exam. This outcome measure is prespecified for the extended wear arms (Air Optix plus HydraGlyde Multifocal Extended Wear and Biofinity Multifocal Extended Wear).

    7. Incidence of microbial keratitis - Daily Wear [Up to Year 1]

      The subject's chart will be reviewed for incidences of microbial keratitis occurring after the baseline exam. This outcome measure is prespecified for the daily wear arms (Air Optix plus HydraGlyde Multifocal Daily Wear and Biofinity Multifocal Daily Wear).

    8. Incidence of microbial keratitis - Extended Wear [Up to Year 3]

      The subject's chart will be reviewed for incidences of microbial keratitis occurring after the baseline exam. This outcome measure is prespecified for the extended wear arms (Air Optix plus HydraGlyde Multifocal Extended Wear and Biofinity Multifocal Extended Wear).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Key Inclusion Criteria:
    • Best Corrected Visual Acuity (BCVA) of 20/25 Snellen or better in each eye at baseline;

    • Must have worn or be wearing Air Optix plus Hydraglyde Multifocal or Biofinity Multifocal for at least 1 year in a daily wear modality, or 3 years in an extended wear modality;

    • Other protocol-defined inclusion criteria may apply.

    Exclusion Criteria:
    • Any recurrent history or active anterior segment infection, inflammation or abnormality contraindicating regular contact lens wear at baseline;

    • Use of systemic or ocular medications contraindicating regular contact lens wear at baseline and/or during the period of the retrospective chart collection;

    • Slit lamp findings, including signs of pathological dry eye, that would contraindicate regular contact lens wear;

    • Participation of the patient in a contact lens or contact lens care product trial during the period of the retrospective chart collection;

    • Other protocol-defined exclusion criteria may apply.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Alcon Research

    Investigators

    • Study Director: Clinical Trial Lead, Vision Care, Alcon Research, LLC

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Alcon Research
    ClinicalTrials.gov Identifier:
    NCT05886894
    Other Study ID Numbers:
    • CLJ241-N003
    First Posted:
    Jun 2, 2023
    Last Update Posted:
    Jun 2, 2023
    Last Verified:
    May 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 2, 2023